卡维地洛与美托洛尔对照治疗原发性高血压60例

目的:评价卡维地洛对原发性高血压的临床疗效及安全性.方法:60例原发性高血压患者经过2周安慰剂洗脱期后随机分为:对照组30例给予美托洛尔25mg,bid,服药2周末血压下降未达有效标准增至50mg,bid,疗程共8周.治疗组给予卡维地洛10mg,bid,服药2周末血压下降未达有效标准者增至20mg,bid,疗程共8周.结果:治疗组降压总有效率80.0%,显效率56.7%,对照组总有效率73.3%,显效率53.3%;两组疗效比较差异无显著性(P>0.05),不良反应发生率差异无显著性(P>0.05).不良反应程度轻微,可耐受.结论:卡维地洛是治疗原发性高血压的安全有效的药物.

Comparative study of carvedilol to metoprolol for the treatment of essential hypertension in 60 patients

Objective:To evaluate the efficacy and safety of carvedilol in the treatment of essential hypertension. Methods:Following after the 2-weeks washing out period,sixty patients with essential hypertension were equally randomized to orally receive cavedilol (10mg,bid) or metoprodol (25mg, bid) for 2 weeks. The patients who did not respond to the 2-week course of therapy, the dosage of cavedilol or metoprolol were escalated to 50mg bid or 20 mg bid for 8 weeks, respectively. Results: At the end of 8-week course of therapy,patients treated with cavedilol and metoprolol achieved overall response rate at 80.0% vs.73.3% ( P >0.05),respectively,and complete response rate at (?)56.7% vs. 53.3% (P>0.05) respectively. The carvedilol was well tolerated across the study with mild ADRs. Conclusion:Carvedilol is effective and safe in the treatment of essential hypertension.